Skip to content
Screener

Veracyte VCYT Biopharmaceutical and other revenue — Cost of Revenue

Other product segments

Testing revenue
$33.31M+17.9%

Similar metrics at other companies

TMH
TMHCAmenity and other revenue — Cost of Revenue
$10.3M+7.6%
TMH
TMHCAll other cost of revenue — Cost of Revenue
$46.75M+13.0%
TMH
TMHCLand closings revenue — Cost of Revenue
$12M+244%
BridgeBio Pharma logo
BBIOCost of license, services, and royalty revenue — Cost of Revenue
$2.21M+265%
Core Scientific, Inc. logo
CORZColocation revenue — Cost of Revenue
$56.69M+501%
Service Corporation International logo
SCIProduct and Service, Other — Cost of Revenue
$288.88M+5.8%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$3.71B+97.6%
Enterprise value$3.48B+104%
P/E42.2×-29.1×
P/S6.9×+2.9×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The source filing: Veracyte’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 8:07 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001384101-26-000031
Line itemThree Months Ended March 31, 20262025
Cost of revenue:
Cost of testing revenue33,30628,260
Cost of product revenue1,8911,422
Cost of biopharmaceutical and other revenue82,698
Intangible asset amortization - cost of revenue2,7072,585
Total cost of revenue37,91234,965
Gross profit101,15979,508
Operating expenses:

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Veracyte's biopharmaceutical and other revenue — cost of revenue?
Veracyte (VCYT) reported biopharmaceutical and other revenue — cost of revenue of $8K in Q1 2026.
How has Veracyte's biopharmaceutical and other revenue — cost of revenue changed year-over-year?
Veracyte's biopharmaceutical and other revenue — cost of revenue decreased by 99.7% year-over-year, from $2.7M to $8K.
What is the long-term trend for Veracyte's biopharmaceutical and other revenue — cost of revenue?
Over 4 years (2021 to 2025), Veracyte's biopharmaceutical and other revenue — cost of revenue has grown at a -5.9% compound annual growth rate (CAGR), from $9.65M to $7.58M.
What does biopharmaceutical and other revenue — cost of revenue mean?
This metric captures the direct costs associated with delivering biopharmaceutical services and research collaborations, including labor, materials, and overhead directly attributable to these contracts. Monitoring this figure helps assess the direct profitability and operational efficiency of the company's non-diagnostic revenue streams.

Ask your AI about Veracyte's biopharmaceutical and other revenue — cost of revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude